TRAPPC10

Across TCGA pan-cancer cohorts, TRAPPC10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAPPC10 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TRAPPC10 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated TRAPPC10 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

BLCA, SKCM, and HNSC are the cancer types where TRAPPC10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.414	.015	20	view →
SKCM	DFS	Median	All	0.923	0.596	.010	14	view →
HNSC	OS	Median	III,IV	0.198	0.745	.003	9	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	3	view →
UCEC	DFS	Median	II,III,IV	0.827	0.305	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAPPC10–BLCA (OS)

Open the BLCA breakdown →